keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/29313934/ultrasonography-a-useful-tool-for-detecting-tumour-pseudoprogression
#1
M Akiyama
No abstract text is available yet for this article.
December 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29303787/supportive-care-in-the-era-of-immunotherapies-for-advanced-non-small-cell-lung-cancer
#2
Gil Awada, Jean Klastersky
PURPOSE OF REVIEW: The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting. These immunotherapies are associated with a distinct toxicity profile based on autoimmune organ toxicity which is a new challenge for supportive care during treatment with these drugs...
January 4, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29239190/-comparison-of-recist-1-1-and-irecist-for-response-evaluation-in-solid-tumours
#3
Š Houdek, T Büchler, E Kindlová
BACKGROUND: Immunotherapy is a relatively new and developing modality in oncological treatment, which may significantly improve treatment results for some patients with malignant tumors. With the increasing number of clinical trials, the demand for a suitable tool to assess and compare treatment responses is growing. Currently, the most common response assessment system for solid tumors is RECIST (response Evaluation Criteria in Solid Tumors) version 1.1. However, in immuno-oncology, a small percentage of patients manifest a new response pattern termed pseudoprogression, in which, after the initial increase in tumor burden or after the discovery of new lesions, a response or at least a prolonged stabilization of the disease can occur...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29218626/treatment-related-changes-in-glioblastoma-a-review-on-the-controversies-in-response-assessment-criteria-and-the-concepts-of-true-progression-pseudoprogression-pseudoresponse-and-radionecrosis
#4
REVIEW
P D Delgado-López, E Riñones-Mena, E M Corrales-García
The assessment of response to therapy in glioblastoma remains a challenge, because the surrogate measures of survival are subject to radiographic misinterpretation. A solid and reliable definition of progression is needed for both clinical decision-making and for evaluating response within the clinical trials. Historically, assessment criteria have used radiologic and clinical features aimed to correctly classify patients into progressive or non-progressive disease. The widely used RANO criteria are a valuable tool in disease evaluation, both in the clinical setting and in the clinical trials...
December 7, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29207418/neuroimaging-of-brain-tumors-pseudoprogression-pseudoresponse-and-delayed-effects-of-chemotherapy-and-radiation
#5
Jörg Dietrich, Sebastian F Winter, Joshua P Klein
No abstract text is available yet for this article.
October 2017: Seminars in Neurology
https://www.readbyqxmd.com/read/29205200/immunotherapy-in-metastatic-urothelial-carcinoma-focus-on-immune-checkpoint-inhibition
#6
REVIEW
Arlene Siefker-Radtke, Brendan Curti
Immunotherapy has been used in localized urothelial carcinoma for decades, especially in the treatment of superficial disease, in which instillation of BCG is a commonly used treatment option. Clinical investigations based on new insights into the immunogenic potential of metastatic urothelial carcinoma have led to the accelerated FDA approval of the immune checkpoint inhibitors atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab. Preliminary findings suggest additional benefits of combinations of immunotherapeutic agents as a future treatment approach in metastatic urothelial carcinoma...
December 5, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29198327/critical-features-and-challenges-associated-with-imaging-in-patients-undergoing-cancer-immunotherapy
#7
REVIEW
Cinzia Solinas, Michele Porcu, Zuzana Hlavata, Pushpamali De Silva, Marco Puzzoni, Karen Willard-Gallo, Mario Scartozzi, Luca Saba
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the paradigms of cancer treatment. Peculiar patterns and kinetics of response have been observed with these new drugs, rendering the assessment of tumor burden particularly challenging in cancer immunotherapy. The mechanisms of action for immune checkpoint blockade, based upon engagement of the adaptive immune system, can generate unusual response patterns, including pseudoprogression, hyperprogression, atypical and delayed responses...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29193849/apparent-transverse-relaxation-r2%C3%A2-on-mri-as-a-method-to-differentiate-treatment-effect-pseudoprogression-versus-progressive-disease-in-chemoradiation-for-malignant-glioma
#8
Jean-Guy Belliveau, Glenn S Bauman, David Macdonald, Maria Macdonald, L Martyn Klassen, Ravi S Menon
INTRODUCTION: Pseudoprogression (psPD) is a transient post-treatment imaging change that is commonly seen when treating glioma with chemotherapy and radiation. The use of apparent transverse relaxation rate (R2∗), which is calculated from a contrast-free multi-echo gradient echo Magnetic Resonance Imaging (MRI) sequence, may allow for quantitative identification of patients with suspected psPD. METHODS: We acquired a multi-echo gradient echo sequence using a 3T-Siemens Prisma MRI...
November 30, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29182990/patterns-of-responses-in-metastatic-nsclc-during-pd-1-or-pdl-1-inhibitor-therapy-comparison-of-recist-1-1-irrecist-and-irecist-criteria
#9
M Tazdait, L Mezquita, J Lahmar, R Ferrara, F Bidault, S Ammari, C Balleyguier, D Planchard, A Gazzah, J C Soria, A Marabelle, B Besse, C Caramella
BACKGROUND: Immune checkpoint inhibitors are an important tool in the therapeutic strategy against metastatic non-small cell lung cancer (NSCLC); however, radiological evaluation is challenging due to the emergence of atypical patterns of responses. Several evaluation criteria have been proposed, such as the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, immune -related RECIST (irRECIST) and iRECIST, but have not been systematically compared in a homogeneous population...
November 25, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29164057/diagnostic-and-prognostic-significance-of-methionine-uptake-and-methionine-positron-emission-tomography-imaging-in-gliomas
#10
REVIEW
Kamalakannan Palanichamy, Arnab Chakravarti
The present most common image diagnostic tracer in clinical practice for glioma is (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for brain tumors diagnosis and prognosis. PET is a promising molecular imaging technique, which provides real-time information on the metabolic behavior of the tracer. The diffusive nature of glioblastoma (GBM) and heterogeneity often make the radiographic detection by FDG-PET inaccurate, and there is no gold standard. FDG-PET often leads to several controversies in making clinical decisions due to their uptake by normal surrounding tissues, and pose a challenge in delineating treatment-induced necrosis, edema, inflammation, and pseudoprogression...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29162045/serial-pseudoprogression-of-metastatic-malignant-melanoma-in-a-patient-treated-with-nivolumab-a-case-report
#11
Yukinori Ozaki, Junichi Shindoh, Yuji Miura, Hiromichi Nakajima, Ryosuke Oki, Miyuki Uchiyama, Jun Masuda, Keiichi Kinowaki, Chihiro Kondoh, Yuko Tanabe, Tsuyoshi Tanaka, Shusuke Haruta, Masaki Ueno, Shigehisa Kitano, Takeshi Fujii, Harushi Udagawa, Toshimi Takano
BACKGROUND: Pseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports yet of pseudoprogression events documented twice during treatment. CASE PRESENTATION: A 55-year-old man underwent surgery for locally advanced esophageal malignant melanoma and received postoperative adjuvant interferon therapy...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29140135/pseudoprogression-on-bevacizumab-treatment-tumor-dynamics-in-the-modern-era-of-systemic-treatment-for-metastatic-colorectal-cancer
#12
Cornelis J A Punt, Joost Huiskens, Thomas van Gulik, Marc Engelbrecht
No abstract text is available yet for this article.
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29131763/immune-checkpoint-inhibitor-cancer-therapy-spectrum-of-imaging-findings
#13
Gary X Wang, Vikram Kurra, Justin F Gainor, Ryan J Sullivan, Keith T Flaherty, Susanna I Lee, Florian J Fintelmann
Immune checkpoint inhibitors are a new class of cancer therapeutics that have demonstrated striking successes in a rapid series of clinical trials. Consequently, these drugs have dramatically increased in clinical use since being first approved for advanced melanoma in 2011. Current indications in addition to melanoma are non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. A small subset of patients treated with immune checkpoint inhibitors undergoes an atypical treatment response pattern termed pseudoprogression: New or enlarging lesions appear after initiation of therapy, thereby mimicking tumor progression, followed by an eventual decrease in total tumor burden...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29118225/activity-of-entrectinib-in-a-patient-with-the-first-reported-ntrk-fusion-in-neuroendocrine-cancer
#14
Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, Pratik Multani
Despite advances in genomic analysis, the molecular origin of neuroendocrine tumors (NETs) is complex and poorly explained by described oncogenes. The neurotrophic TRK family, including NTRK1, 2, and 3, encode the proteins TRKA, TRKB, TRKC, respectively, involved in normal nerve development. Because NETs develop from the diffuse neuroendocrine system, we sought to determine whether NTRK alterations occur in NETs and whether TRK-targeted therapy would be effective. A patient with metastatic well-differentiated NET, likely of the small intestine, was enrolled on the STARTRK2 trial (ClinicalTrials...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29105360/pseudoprogression-as-an-adverse-event-of-glioblastoma-therapy
#15
Carmen Balaña, Jaume Capellades, Estela Pineda, Anna Estival, Josep Puig, Sira Domenech, Eugenia Verger, Teresa Pujol, Maria Martinez-García, Laura Oleaga, JoseMaria Velarde, Carlos Mesia, Rafael Fuentes, Jordi Marruecos, Sonia Del Barco, Salvador Villà, Cristina Carrato, Oscar Gallego, Miguel Gil-Gil, Jordi Craven-Bartle, Francesc Alameda
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21...
November 3, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29104864/imaging-therapy-response-of-gastrointestinal-stromal-tumors-gist-with-fdg-pet-ct-and-mri-a-systematic-review
#16
REVIEW
Antonia Dimitrakopoulou-Strauss, Ulrich Ronellenfitsch, Caixia Cheng, Leyun Pan, Christos Sachpekidis, Peter Hohenberger, Thomas Henzler
Purpose: Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods: PubMed and Cochrane library search were performed using appropriate keywords...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29103145/increased-signal-intensity-within-glioblastoma-resection-cavities-on-fluid-attenuated-inversion-recovery-imaging-to-detect-early-progressive-disease-in-patients-receiving-radiotherapy-with-concomitant-temozolomide-therapy
#17
Luke A Perry, Panagiotis Korfiatis, Jay P Agrawal, Bradley J Erickson
PURPOSE: Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy. METHODS: In this retrospective study approved by our Institutional Review Board, we evaluated the records of 122 consecutive patients with partially or totally resected glioblastoma...
November 4, 2017: Neuroradiology
https://www.readbyqxmd.com/read/29098766/some-statistical-considerations-in-the-clinical-development-of-cancer-immunotherapies
#18
Bo Huang
Immuno-oncology has emerged as an exciting new approach to cancer treatment. Common immunotherapy approaches include cancer vaccine, effector cell therapy, and T-cell-stimulating antibody. Checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/L1 antagonists have shown promising results in multiple indications in solid tumors and hematology. However, the mechanisms of action of these novel drugs pose unique statistical challenges in the accurate evaluation of clinical safety and efficacy, including late-onset toxicity, dose optimization, evaluation of combination agents, pseudoprogression, and delayed and lasting clinical activity...
November 2, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/29074633/comparison-between-the-prebolus-t1-measurement-and-the-fixed-t1-value-in-dynamic-contrast-enhanced-mr-imaging-for-the-differentiation-of-true-progression-from-pseudoprogression-in-glioblastoma-treated-with-concurrent-radiation-therapy-and-temozolomide-chemotherapy
#19
J G Nam, K M Kang, S H Choi, W H Lim, R-E Yoo, J-H Kim, T J Yun, C-H Sohn
BACKGROUND AND PURPOSE: Glioblastoma is the most common primary brain malignancy and differentiation of true progression from pseudoprogression is clinically important. Our purpose was to compare the diagnostic performance of dynamic contrast-enhanced pharmacokinetic parameters using the fixed T1 and measured T1 on differentiating true from pseudoprogression of glioblastoma after chemoradiation with temozolomide. MATERIALS AND METHODS: This retrospective study included 37 patients with histopathologically confirmed glioblastoma with new enhancing lesions after temozolomide chemoradiation defined as true progression (n = 15) or pseudoprogression (n = 22)...
October 26, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29050959/sequential-proton-boost-after-standard-chemoradiation-for-high-grade-glioma
#20
Sebastian Adeberg, Denise Bernhardt, Semi Ben Harrabi, Matthias Uhl, Angela Paul, Nina Bougatf, Vivek Verma, Andreas Unterberg, Wolfgang Wick, Thomas Haberer, Stephanie E Combs, Klaus Herfarth, Juergen Debus, Stefan Rieken
PURPOSE: To retrospectively assess the feasibility and safety of a sequential proton boost following conventional chemoradiation in high-grade glioma (HGG). METHOD AND MATERIALS: Sixty-six consecutive patients with HGG were treated with 50.0 Gy photons (50.0-50.4 Gy) in 2.0 Gy (1.8-2.0 Gy) fractions, followed by a proton boost with 10 Gy equivalent (Gy(RBE)) in 2.0 Gy(RBE) fractions. Patients were matched one to one with 66 patients with HGG undergoing conventional radiation therapy (RT) with 60...
October 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"